Khiron Life Sciences Corp. announced this week that the company has entered into an exclusive 2-year agreement with Farmacia Universal S.A.C. of Perú, a leading pharmacy chain and manufacturing laboratory based in Lima.
The agreement is for Khiron to manufacture and distribute Khiron-branded medical cannabis magistral preparations in Perú.
According to the company’s press release, only registered pharmaceutical establishments who have fulfilled GSP requirements are authorized to participate in wholesale import and commercialization of cannabis products in Peru. The Company expects to begin sales in Peru once it obtains its import license from DIGEMID and Farmacia Universal S.A.C. receives authorization for commercialization from DIGEMID.
“Khiron is currently the only Colombian Company with high-THC quotas for export purposes, including into Peru , and considers the country one of the key medical cannabis markets in Latam. Based on our regulatory expertise, Khiron has demonstrated an ability to work with the Peruvian regulatory framework and believes that it will be successful in securing additional permits.” said Andres Galofre , Khiron VP, Business Development. “Our clinics, with 120,000 patients, provide a model we can replicate in different jurisdictions, including Peru , subject to their regulatory framework.”
Khiron Perú SA has already obtained certifications as a Pharmaceutical Entity with Good Storage Practices (GSP. The Company obtained approval of its security protocols from the Anti-Narcotics Unit of the Ministry of Interior (DIRANDRO) in December of last year and subsequently submitted its application for import license for medical marijuana.
